# Pegilodecakin

Source: https://onco.cc/drugs/pegilodecakin/  
OnCo record `pegilodecakin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pegilodecakin, a long-acting interleukin-10 meant to expand tumour-killing T cells, added nothing to FOLFOX in the phase 3 SEQUOIA trial of second-line pancreatic cancer, and Eli Lilly dropped it.

## Summary

Pegylated interleukin-10 raised CD8 T cell activity in early studies, and ARMO BioSciences (bought by Eli Lilly in 2018) took it into SEQUOIA: 567 patients whose metastatic pancreatic cancer had progressed on gemcitabine-based therapy (94.7 percent after gemcitabine and nab-paclitaxel) randomised to FOLFOX with or without pegilodecakin. Median overall survival was 5.8 against 6.3 months (hazard ratio 1.045), progression-free survival 2.1 months in both arms and response 4.6 against 5.6 percent; thrombocytopenia (55 against 20 percent) and anaemia (40 against 16 percent) were commoner with the cytokine while immune markers moved as predicted. Five UK sites took part (Cambridge, Hammersmith, Velindre Cardiff, University College London Hospitals, Guy's and St Thomas').

## Fields

- Kind: Treatment
- Status: negative
- Last checked: 2026-09-24
- Also known as: AM0010; Pegylated interleukin-10
- Code: AM0010, LY3500518
- Modality: PEGylated recombinant human interleukin-10 (cytokine)
- Mechanism: Interleukin-10 receptor agonism, expanding and activating tumour-infiltrating CD8 T cells while suppressing inflammatory myeloid signalling.

## Sources

- Hecht et al., SEQUOIA (JCO 2021): https://doi.org/10.1200/JCO.20.02232
- ClinicalTrials.gov NCT02923921: https://clinicaltrials.gov/study/NCT02923921

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- terms: [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/), [Pancreatic cancer: the failed and stopped programmes and why](https://onco.cc/terms/pancreatic-failed-programmes/)
- trials: [SEQUOIA](https://onco.cc/trials/sequoia/)

---
JSON: https://onco.cc/api/v1/entities/pegilodecakin.json